EGFR and non-small cell lung carcinoma: Although different TKIs have similar mechanisms of action, they differ in terms of targeting kinase profiles, pharmacokinetics (PK), and side effects.30 For example, osimertinib is a third-generation TKI targeting EGFR for NSCLC with specific mutations.